Event
HPTN at HIVR4P 2024
Lima, Peru
At HIVR4P 2024, the 5th HIV Research for Prevention Conference, HPTN researchers presented 15 oral and poster presentations covering a multitude of HPTN studies. This conference fosters interdisciplinary knowledge exchange on HIV vaccines, microbicides, PrEP, treatment as prevention, and biomedical interventions, as well as their social and behavioral implications.
Presented Research
- The choice of indicators influences who is identified as priority populations for HIV epidemic response: a combined analysis of 15 mathematical models from 10 African countries – Romain Silhol
- Pharmacokinetic interaction assessment of the HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 HIV prevention trials HVTN127/HPTN087, HVTN130/HPTN089 and HVTN136/HPTN092 – Tariro Dianah Chawana
- Analytical treatment interruption (ATI) in Peru among MSM & GNC individuals with early ART initiation +/- VRC01 proximate to HIV acquisition: Stakeholder engagement & early clinical data – Jorge Gallardo-Cartagena
- Phase 1 dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics and neutralization activity of PGDM1400LS in combination with VRC07-523LS and PGT121.414.LS in healthy participants without HIV (HVTN 140/HPTN 101) – Sharana Mahomed
- Assessment of infusion-related reactions after intravenous administration of HIV monoclonal antibodies PGT121.414.LS, PGDM1400.LS or VRC07-523LS (alone or in combination with PGT121, PGDM1400, 10-1074, PGT121.414.LS, PGDM1400.LS), in five phase 1 studies – Silvia P Goulart
- Evaluation of potential pharmacologic interactions between CAB-LA or TDF/ FTC and hormonal contraceptive agents: a tertiary analysis of HPTN 084 – Mark Marzinke
- PrEP uptake and adherence among TGW: findings from a randomized clinical trial of a multicomponent intervention (HPTN 091) – Tonia Poteat
- “I am definitely smart enough to make this decision and I know what I’m doing”: self-efficacy and HIV prevention education in the first US adolescent, CAB-LA PrEP study (HPTN 083-01) – Amber Babinec
- Exploring relationship dynamics: the impact of disclosure and partner influence on oral and injectable PrEP adherence among users and their intimate partners (HPTN 084 qualitative findings) – Makhosazane Nomhle Ndimande-Khoza
- Engaging community stakeholders in preparation for HPTN 091 – Jonathan Lucas
- HVTN 805/HPTN 093/A5393 Analytical Treatment Interruption (ATI) among African women with early ART initiation +/- VRC01 received within 8 weeks of HIV acquisition: safety, viral rebound and virologic control – Shelly Karuna
- Engagement and training of barbers to deliver an HIV prevention intervention to their clients (HPTN 111) – Joel Maena
- Acceptability of intravenous (IV) and subcutaneous (SC) infusion administration of monoclonal antibody (mAb) combinations: VRC07-523LS with PGT121, PGDM1400, PGT121.414.LS and PGDM1400LS in phase 1 anti-HIV mAb trials – Maija Alanya Anderson
- Facilitators, barriers and robust informed consent for HVTN805/HPTN093/A5393 analytical treatment interruption (ATI) participation: insights from ATI participants and decliners screened from the antibody mediated prevention (AMP) study in Southern Africa – Shelly Karuna
- Recommendations made during Community consultations for analytical treatment interruption (ATI) HIV research studies in Southern Africa – Matshidiso Adelaide Malefo
- Can intention studies predict PrEP uptake? Systematic review and meta-analysis of PrEP studies on intention and uptake across populations in sub-Saharan Africa – Jose Luis Paredes